✦ LIBER ✦

Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer

✍ Scribed by Theera Umsawasdi; Manuel Valdivieso; Daniel J. Booser; H. Thomas Barkley Jr; Michael Ewer; Bruce Mackay; Hari M. Dhingra; William K. Murphy; Gary Spitzer; Delia F. Chiuten; Calvin Dixon; Peter Farha; David T. Carr

Publisher: John Wiley and Sons
Year: 1989
Tongue: English
Weight: 579 KB
Volume: 64
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19891115)64:10<1995::aid-cncr2820641004>3.0.co;2-l

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pilot study of cyclophosphamide-doxorubi

Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer

✍ Taisuke Ohnoshi; Shunkichi Hiraki; Hiroshi Ueoka; Katsuyuki Kiura; Haruhito Kame 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 508 KB

Oral combination antiemetics in patients

Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin

✍ Lorraine Baltzer Cleri; Mark G. Kris; Leslie B. Tyson; Katherine M. W. Pisters; 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 526 KB

A phase II study of methotrexate, doxoru

A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer

✍ Gianfranco Buccheri; D. Ferrigno; A. Rosso 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 826 KB

The addition of cisplatin to cyclophosph

The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma : A randomized study of 457 patients

✍ Thierry Urban; Claude Chastang; François-Xavier Lebas; Jean-Paul Duhamel; Guy Ad 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## BACKGROUND. To assess whether the addition of cisplatin (100 mg/m 2 administered intravenously on Day 1) to CDE (cyclophosphamide [1000 mg/m 2 on Day 1], doxorubicin [45 mg/m 2 on Day 1], and etoposide [150 mg/m 2 on Days 1 and 2] combination is useful in the treatment of patients with small cel

A randomized trial of hybrid administrat

A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/Cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma : Results of long term follow-up

✍ Hiroshi Ueoka; Katsuyuki Kiura; Masahiro Tabata; Haruhito Kamei; Kenichi Gemba; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 2 views

## BACKGROUND. In an attempt to determine the efficacy of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) hybrid chemotherapy (HYB), a rapidly alternating chemotherapy, in patients with small cell lung carcinoma (SCLC), the authors conducted a randomized study to